Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Rossari Biotech Limited (ROSSARI.NS)
Mumbai, IN
Rossari Biotech Limited, an India-based company, is a global manufacturer and distributor of specialized chemical products. Its diverse offerings cater to numerous industries, including ingredients for soaps and detergents, formulations for inks, paints, and coatings, materials for ceramics and tiles, solutions for pulp and paper production, components for cement, and water treatment compounds. The company also provides a broad spectrum of textile processing chemicals, supporting various fabrics like cotton, polyester, acrylic, wool, silk, and nylon, alongside functional finishes, denim treatments, and eco-friendly options. Additionally, Rossari Biotech develops pet grooming essentials such as natural shampoos, powders, deodorants, sprays, creams, and floor cleaners, marketed under brands like Lozalo, Hunger Fills, and Sniffy. Its portfolio extends to poultry nutrition products, encompassing vitamin-mineral blends, toxin binders, enzyme preparations, liquid nutraceuticals, and herbal supplements. Founded in 2003, the firm, initially named Rossari Labtech, rebranded to Rossari Biotech Limited in December of the same year and is headquartered in Mumbai, India.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.13% | -3.49% | -5.49% | +12.92% | -13.91% | -13.43% | -25.68% | -40.22% | -59.41% | -32.05% | -32.05% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-06 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals - Specialty: +4.7%+15.2% ★ Q1'26: +18.2% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +13.2%+9.3% Q1'26: +33.5% (vs Q1'25)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%-1.2% Q1'26: -24.4% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +8.8%+8.6% Q1'26: +7.8% (vs Q1'25)
-
ROIC Chemicals - Specialty: +5.6%+9.3% ★ Q1'26: +9.4% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.1%+0.1% Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×1.52× Q1'26: 1.41× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 4 Rev. Ana. 4 EPS Ana. |
Mar 2027 3 Rev. Ana. 4 EPS Ana. |
Mar 2028 4 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
7.07B
est: 7.09B (-0.3%)
|
14.83B
est: 14.83B (0.0%)
|
16.56B
est: 16.65B (-0.5%)
|
18.31B
est: 19.10B (-4.1%)
|
20.80B
est: 20.45B (+1.7%)
|
23.22B
22.80B – 23.86B
+13.6% YoY
|
26.90B
26.00B – 27.56B
+15.8% YoY
|
30.20B
28.63B – 31.62B
+12.3% YoY
|
| EBITDA |
1.31B
est: 1.01B (+29.8%)
|
1.94B
est: 2.11B (-8.2%)
|
2.12B
est: 2.37B (-10.6%)
|
2.57B
est: 2.47B (+4.3%)
|
2.65B
est: 2.64B (+0.4%)
|
3.00B
2.94B – 3.08B
+13.6% YoY
|
3.47B
3.36B – 3.56B
+15.8% YoY
|
3.90B
3.70B – 4.08B
+12.3% YoY
|
| EBIT |
1.08B
est: 771.34M (+40.2%)
|
1.46B
est: 1.61B (-9.7%)
|
1.52B
est: 1.81B (-16.2%)
|
1.97B
est: 1.82B (+8.1%)
|
1.98B
est: 1.95B (+1.5%)
|
2.22B
2.18B – 2.28B
+13.6% YoY
|
2.57B
2.48B – 2.63B
+15.8% YoY
|
2.88B
2.73B – 3.02B
+12.3% YoY
|
| Net Income |
802.20M
est: 1.09B (-26.1%)
|
976.74M
est: 1.01B (-3.2%)
|
1.07B
est: 984.50M (+8.9%)
|
1.31B
est: 1.36B (-4.2%)
|
1.36B
est: 1.35B (+1.0%)
|
1.38B
1.30B – 1.46B
+2.2% YoY
|
1.58B
1.52B – 2.01B
+14.3% YoY
|
2.09B
1.91B – 2.26B
+32.1% YoY
|
| SGA |
566.31M
est: 392.01M (+44.5%)
|
634.85M
est: 819.61M (-22.5%)
|
828.38M
est: 919.92M (-10.0%)
|
813.29M
est: 1.21B (-32.6%)
|
1.23B
est: 1.29B (-5.0%)
|
1.47B
1.44B – 1.51B
+13.6% YoY
|
1.70B
1.64B – 1.74B
+15.8% YoY
|
1.91B
1.81B – 2.00B
+12.3% YoY
|
| EPS |
15.58
est: 19.60 (-20.5%)
|
17.81
est: 18.22 (-2.3%)
|
19.46
est: 17.78 (+9.4%)
|
23.67
est: 24.69 (-4.1%)
|
24.66
est: 25.08 (-1.7%)
|
25.04
23.47 – 26.36
-0.2% YoY
|
32.95
27.52 – 36.19
+31.6% YoY
|
38.50
34.43 – 40.85
+16.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-12 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-06-11 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-06-10 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-06-09 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-06-08 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-06-05 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-06-04 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-06-03 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-06-02 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-06-01 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-29 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-27 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-26 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-25 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-22 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-21 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-20 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-19 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-18 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-15 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-14 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-13 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-12 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-11 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-08 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-05 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-04 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-29 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 92.5K | 0.65% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Edward Walter Menezes | Co-Founder & Executive Chairman | 14M | male |
| Sunil Srinivasan Chari | Co-Founder, MD & Director | 11M | male |
| Mikhail Menezes | Director of AHN & Textile Business | — | — |
| Parul Gupta | Head of Legal, Company Secretary & Compliance Officer | — | female |
| Prasad Gadkari | Head of Manufacturing | — | male |
| Puneet Arora | Head of Mergers & Acquisitions and Global Textile Exports | — | male |
| Sandeep Tulshyan | Head of Strategic Supply Chain & Procurement | — | male |
| Ketan Sablok | Group Chief Financial Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ROSSARI.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
